Ad5-EBOV

AXP000173.1 · Vaccine

Platform
human adenovirus 5 (non-replicating)
Targets
Zaire ebolavirus GP
Originator
Beijing Institute of Biotechnology
Sponsor
CanSino Biologics

Names

NameTypeSource
Ad5-EBOVpreferred name, codecurator, press
Ad5-EBOV vaccine ambiguoussynonympress

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
replication-defective human adenovirus type 5 encoding Ebola virus glycoprotein
Transgenes
Zaire ebolavirus glycoprotein
Route
intramuscular
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
NMPACN2017approvedPrevention of Ebola virus disease (emergency use stockpile licence)source

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02533791A Booster Dose of Ad5-EBOV in Healthy Adults After Primary ImmunizationCompletedPhase 12015-072015-09110Ebola Virus Disease
NCT02401373A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.CompletedPhase 12015-032015-0761Ebola Virus Disease
NCT02326194A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.CompletedPhase 12014-122015-02120Ebola Virus Disease

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 32213108Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors.mAbs2020name in abstract: Ad5-EBOV
PMID 28017642Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.The Lancet. Global health2017cited by trial NCT02326194
PMID 28362208The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial.Human vaccines & immunotherapeutics2017name in abstract: Ad5-EBOV
PMID 28708962Open-label phase I clinical trial of Ad5-EBOV in Africans in China.Human vaccines & immunotherapeutics2017cited by trial NCT02401373
PMID 25817373Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.Lancet (London, England)2015cited by trial NCT02326194

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38745762A causal multiomics study discriminates the early immune features of Ad5-vectored Ebola vaccine recipients.Innovation (Cambridge (Mass.))2024name in abstract: Ad5-EBOV
PMID 36119119Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus.Frontiers in immunology2022name in abstract: Ad5-EBOV
PMID 32164743Challenges and opportunities for China entering global research and development for emerging infectious diseases: a case study from Ebola experience.Infectious diseases of poverty2020name in abstract: Ad5-EBOV
PMID 31272985Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review.BMJ open2019name in abstract: Ad5-EBOV
PMID 28795602Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice.Human gene therapy2018name in abstract: Ad5-EBOV
PMID 30381976Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer.Human gene therapy. Clinical development2018name in title: Ad5-EBOV

Notes

Recombinant replication-defective human adenovirus type 5 carrying the Ebola virus glycoprotein, developed with the Beijing Institute of Biotechnology; licensed in China in 2017, the country's first Ebola vaccine. Exact approval date, agency name and the Ebola strain used for the glycoprotein were not verified from the sources read.

How to cite

Ad5-EBOV (AXP000173.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000173.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.